CORONAVIRUS/Medigen COVID-19 vaccine takes step forward in Australia

11/22/2021 09:27 PM
To activate the text-to-speech service, please first agree to the privacy policy below.
A woman is given a shot of the Medigen COVID-19 in August. CNA file photo
A woman is given a shot of the Medigen COVID-19 in August. CNA file photo

Taipei, Nov. 22 (CNA) Taiwan's COVID-19 vaccine brand, Medigen, has passed the first hurdle in getting provisional approval for use of the vaccine in Australia, the country's Therapeutic Goods Administration (TGA) announced Monday.

The TGA said it has decided to grant Medigen Vaccine Biologics Corp's MVC-COV1901 COVID-19 vaccine candidate "provisional determination" status, the first step of the TGA's five-step "provisional approval pathway."

Once the TGA determines that the vaccine is safe and effective, it will eventually get "provisional registration" status -- step three in the process -- allowing it to supply the product to Australia for two years.

According to the TGA, the decision to grant the vaccine provisional determination status came after considering "all eligibility criteria, including factors such as the evidence of a plan to submit comprehensive clinical data and the seriousness of the current COVID-19 pandemic."

Due to Australia's laws, provisional determination was granted to Medigen through Grand Pacific CRO, the Australian sponsor that represents the Taiwanese company.

The Medigen vaccine is the sixth COVID-19 vaccine to be granted "provisional determination" status by the TGA, according to the company.

More AstraZeneca doses have been administered than have been officially received because medical workers can sometimes get more than the standard number of shots from a vial.
More AstraZeneca doses have been administered than have been officially received because medical workers can sometimes get more than the standard number of shots from a vial.

With the first hurdle taken care of, Medigen said it is now compiling the necessary documents to move on to the next step of registering its vaccine in Australia.

After the drug receives "provisional registration," it could potentially circulate in Australia for six years, as step four of the "provisional approval pathway" would grant a two-year "extension of provisional registration" twice once the application is approved.

Following that, Medigen's sponsor, Grand Pacific CRO could then apply for the final step and "transition to full registration" once sufficient clinical data become available to establish the safety and efficacy of the vaccine.

(By Han Ting-ting and James Lo) enditem/ls

View All
0:00
/
0:00
We value your privacy.
Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.